Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in comparison with imatinib, for the main-line cure of CML-CP. Five hundred and nineteen clients with recently diagnosed CML-CP ended up randomly assigned to acquire dasatinib at a dose of 100 mg as soon as day by day (259 https://johnathanwbgjo.blogripley.com/29356556/the-smart-trick-of-epiberberine-that-nobody-is-discussing